Abstracts tagged "immunology"

Abstract Number: 1783 • ACR Convergence 2024
Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Understanding the molecular mechanisms of SLE is crucial for developing effective…
Abstract Number: 1953 • ACR Convergence 2024
The National Trend of Using Prescription Immunosuppressives
Queeneth Edwards¹, Amenah Qotineh¹, Chukwuemelie Okeke² and Jian Zhang¹, ¹Georgia Southern University, statesboro, GA, ²St Georges University, St Georges, Saint George, Grenada
Background/Purpose: Recent data from the 2021 National Health Interview Survey (NHIS) reveals a marked increase in the percentage of adults using immunosuppression. However, data from…
Abstract Number: 2504 • ACR Convergence 2024
Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study
Paul Cioni¹, Yann Nguyen², Julien ROHMER³, Henry Dupuy⁴, Xavier Puéchal⁵, Estibaliz Lazaro⁶, Grégory Pugnet⁷, Cécile-Audrey Durel⁸, Edoardo Conticini⁹, François Lifermann¹⁰, Philip Bielefeld¹¹, pierre duffau⁴, Hartmut Mahrhofer¹², Alexis Régent⁵, Loïc Guillevin¹³, ludovic trefond¹⁴, Christian AGARD¹⁵, Alice Bérezné¹⁶, Valentin Lacombe¹⁷, Perrine SMETS¹⁸, Sophie Georgin-lavialle¹⁹, Arsene Mekinian²⁰ and Benjamin Terrier²¹, and the French Vasculitis Study Group and the French Vexas Group, ¹Cochin University Hospital, Paris, France, ²Université Paris Saclay, Clichy, Ile-de-France, France, ³APHP, Suresnes, France, ⁴Bordeaux University Hospital, Bordeaux, France, ⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁶Bordeaux University Hospital, Pessac, France, ⁷Toulouse Rangueil University Hospital, Toulouse, France, ⁸Edouard Herriot University Hospital, Lyon, France, ⁹University of Siena, Siena, Siena, Italy, ¹⁰Dax Hospital, Dax, France, Dax, France, ¹¹Dijon University Hospital, Dijon, France, ¹²Kirchheim Clinic, Kirchheim unter Teck, Germany, ¹³National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁴Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁵Nantes University Hospital, Nantes, France, ¹⁶Annecy Genevois Hospital, Annecy, France, ¹⁷Angers University Hospital, Angers, France, ¹⁸Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ¹⁹Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²⁰Saint Antoine University Hospital, Paris, France, ²¹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis affecting medium-sized vessels. It is a life-threatening disease without appropriate treatment. In 2024, approximately one quarter…
Abstract Number: 0240 • ACR Convergence 2024
Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Asia-Sophia Wolf², Taissa M. Kasahara³, Kristin H. Bjørlykke⁴, Ingrid Jyssum⁵, Joseph Sexton⁵, Anne Therese Tveter⁵, Guri Solum², Ingrid Fadum Kjønstad², Ingrid E. Christensen⁵, Tore K. Kvien⁶, Jørgen Jahnsen⁷, Espen A. Haavardsholm¹, Ludvig A. Munthe⁸, Sella A. Provan⁵, John Torgils Vaage⁸, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁸, Siri Mjaaland², Silje W. Syversen⁹ and Guro L. Goll⁹, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ³University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁷Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁸Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
Abstract Number: 0962 • ACR Convergence 2024
Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis
Parker Jones¹, Salina Dominguez², Miranda Gurra³, Gaurav Gadhvi⁴, Tyler Therron², Kathleen Aren⁵, Carla Cuda³, Monique Hinchcliff⁶, Harris Perlman³, Hadijat Makinde³ and Deborah Winter⁷, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL, ⁴University of Michigan, Ann Arbor, MI, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Yale School of Medicine, Westport, CT, ⁷Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…
Abstract Number: 1784 • ACR Convergence 2024
T-bet Expressing B Cells as a Putative Prognostic and Therapeutic Biomarker for Human SLE
Athanasios Sachinidis¹, Maria Trachana², Anna Taparkou², George Gavriilidis³, Vasileios Vasileiou³, Sofoklis Keisaris³, Panayotis Verginis⁴, Christina Adamichou⁵, Dimitrios Boumpas⁶ and Alexandros Garyfallos², ¹School of Medicine, Aristotle University of Thessaloniki, Greece, Thessaloniki, Greece, ²Ippokrateio General Hospital Thessaloniki, Thessaloniki, Greece, ³Centre for Research and Technology Hellas, Thessaloniki, Greece, ⁴Medical School, University of Crete, Heraklion, Crete, Greece, ⁵IPPOKRATEION HOSPITAL OF THESSALONIKI, Athens, Greece, ⁶4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece
Background/Purpose: T-bet+ B cells, known as age-associated B cells (ABCs) and/or double-negative B cells (DN), expand in various autoimmune diseases. This study aimed to clarify…
Abstract Number: 1978.5 • ACR Convergence 2024
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Faye Yu¹, Eugene Myshkin², Carolina Bobadilla Mendez³, Marta Cossu⁴, Kaiyin Fei⁵, Qingmin Wang⁶, Matthew J. Loza⁶, Dessislava Dimitrova³ and Sheng Gao³, ¹Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, USA, MA, MA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ⁴Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

Background/Purpose: Nipocalimab is a fully human, high affinity, aglycosylated, effectorless IgG1 monoclonal antibody designed to selectively block neonatal fragment crystallizable receptor (FcRn), thereby lowering IgG…
Abstract Number: 2507 • ACR Convergence 2024
IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil
Frederico Pinheiro¹, Cristina Orikaza², Gerson Keppeke³, Emília Sato² and Alexandre de Souza⁴, ¹Universidade Federal de Sao Paulo - UNIFESP, São Paulo, SP, Brazil, ²Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ³Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, ⁴UNIFESP-EPM, São Paulo, SP, Brazil
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic, fibroinflammatory condition affecting almost all organs. It is a rare entity that is continuously being studied worldwide. It…
Abstract Number: 0241 • ACR Convergence 2024
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Rebecca Sadun¹, Dan Crair¹, Emmanuel Walter¹, Eugene St.Clair², David Pisetsky², Amanda Eudy³, Megan Clowse⁴, Jennifer Rogers⁵, Kai Sun¹, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss¹, Sarah Valencia¹ and M. Athony Moody⁷, ¹Duke University, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Duke University, Raleigh, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University School of Medicine, Durham
Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
Abstract Number: 0967 • ACR Convergence 2024
Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions
Hadijat Makinde¹, Miranda Gurra¹, Salina Dominguez², Matthew Dapas², Tyler Therron², Kathleen Aren³, Marie-Pier Tetreault², Monique Hinchcliff⁴, Deborah Winter⁵ and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Division of Rheumatology, Chicago, IL, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…
Abstract Number: 1786 • ACR Convergence 2024
Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Christian Wright¹, Rufei Lu², Catriona Wagner³, Carla Guthridge⁴, Susan Macwana¹, Eliza Chakravarty⁴, Tammy Utset⁵, Diane Kamen⁶, Gabriel Nicolas Contreras Martin⁷, William McCune⁸, Cynthia Aranow⁹, Kenneth Kalunian¹⁰, Elena Massarotti¹¹, Megan Clowse¹², Brad Rovin¹³, S. Sam Lim¹⁴, Vikas Majithia¹⁵, Richard Looney¹⁶, Maria Dall'Era¹⁷, Doruk Erkan¹⁸, Amit Saxena¹⁹, Nancy Olsen²⁰, Kichul Ko²¹, Ellen Goldmuntz²², William Barry²³, Ashley Pinckney²⁴, ALE06 Clinical Study Team⁴, Judith James⁴ and Joel Guthridge⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²University of California San Francisco, San Bruno, CA, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Chicago, Chicago, IL, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Miami, Key Biscayne, FL, ⁸U Michigan, Ann Arbor, MI, ⁹Feinstein Institutes for Medical Research, New York, NY, ¹⁰University of California San Diego, La Jolla, CA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Duke University, Chapel Hill, NC, ¹³The Ohio State University, Columbus, OH, ¹⁴Emory University, Atlanta, GA, ¹⁵Mayo Clinic Florida, Jacksonville, FL, ¹⁶University of Rochester, Rochester, NY, ¹⁷UCSF, Corte Madera, CA, ¹⁸Hospital for Special Surgery, New York, NY, ¹⁹NYU School of Medicine, New York, NY, ²⁰Penn State University/Milton S Hershey, Hershey, PA, ²¹The University of Chicago, Chicago, IL, ²²NIAID/ NIH, Washington, DC, ²³Rho, Inc, Durham, NC, ²⁴Rho, St Louis Park, NC
Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
Abstract Number: 1983 • ACR Convergence 2024
Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
Aaron Teel¹, Adrian Grebowicz², Mats Junek³, Stephanie Garner⁴, Tom Appleton⁵ and Faiza Khokhar⁶, ¹London Health Sciences Centre, Sarnia, ON, Canada, ²Western University, London, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada, ⁶McMaster University, St. Joseph's Hamilton, Mississauga, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy that have been associated with immune-related adverse events (irAEs). These include multiple rheumatic diseases…
Abstract Number: 2521 • ACR Convergence 2024
Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis
Michael Putman¹, Nader Khalidi², Carol Langford³, Curry Koening⁴, Christian Pagnoux⁵, David Cuthbertson⁶, Carol McAlear⁷ and Peter Merkel⁷, and the Vasculitis Clinical Research Consortium (VCRC), ¹The Medical College of Wisconsin, Milwaukee, WI, ²McMaster University, Hamilton, ON, Canada, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶University of South Florida, Tampa, FL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Macrophages play a central role in the pathogenesis of giant cell arteritis (GCA), but few studies have correlated macrophage phenotype or topography from temporal…
Abstract Number: 0248 • ACR Convergence 2024
Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
Nadia Aikawa¹, Ana Cristina Medeiros-Ribeiro², Sandra Pasoto³, Leonard Kupa³, Luciana Seguro⁴, ANA PAULA ASSAD³, Eduardo Borba³, Carla Goncalves Schahin Saad⁴, Emily Figueiredo Neves Yuki³, Danieli Andrade⁵, Andrea Shimabuco⁴, Karina Bonfiglioli³, Diogo Domiciano³, Julio Moraes³, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Henrique Giardini³, Joao de Oliveira³, Isabele Antonelli³, Renata Pinheiro³, Thais Bonini³, Marta Lopes⁶, Clovis Silva⁷ and Eloisa Bonfa³, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Infectious Disease Department, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) due to their condition and treatment. The new recombinant vaccine…
Abstract Number: 1009 • ACR Convergence 2024
Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept
Kevin Winthrop¹, Jeremy Hawkins², Adriana Weinberg³, Sarah Siegel², Jessica Baxter³, Krystle Garth³, Joseph Huffstutter⁴, James Loveless⁵, Suzanne gharib⁶, Shanmugapriya (Priya) Reddy⁷, Jayashree Sinha⁸, Elvia Moreta⁹, David Ridley¹⁰, Ilhem Messaoudi¹¹ and Jeffrey Curtis¹², ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³University of Colorado, Aurora, CO, ⁴Arthritis Associates PLLC, Signal Mountain, TN, ⁵St Luke's Health System, Boise, ID, ⁶Charleston Area Medical Center, Charleston, MD, ⁷Southwest Florida Rheumatology, Riverview, FL, ⁸self employed, Clovis, NM, ⁹St. Paul Rheumatology, Eagan, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹University of Kentucky, Lexington, ¹²University of Alabama at Birmingham, Hoover, AL
Background/Purpose: The adjuvanted recombinant glycoprotein E (gE) herpes zoster vaccine (RZV) received expanded approval for use in 2021 for adults receiving immunosuppression. Despite approval, little…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].